Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Merck
Colorcon
McKinsey
Medtronic

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Bryostatin 1

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Bryostatin 1?

Bryostatin 1 is an investigational drug.

There have been 40 clinical trials for Bryostatin 1. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 1997.

The most common disease conditions in clinical trials are Lymphoma, Leukemia, and Lymphoma, Non-Hodgkin. The leading clinical trial sponsors are National Cancer Institute (NCI), Barbara Ann Karmanos Cancer Institute, and Virginia Commonwealth University.

Recent Clinical Trials for Bryostatin 1
TitleSponsorPhase
A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's DiseaseNeurotrope Bioscience, Inc.Phase 2
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral TreatmentFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalPhase 1
Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's DiseaseBlanchette Rockefeller Neurosciences InsitutePhase 1/Phase 2

See all Bryostatin 1 clinical trials

Clinical Trial Summary for Bryostatin 1

Top disease conditions for Bryostatin 1
Top clinical trial sponsors for Bryostatin 1

See all Bryostatin 1 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Merck
Harvard Business School
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.